Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21194023 | 0.64 | AKR1C3 (0.54) | TDP1AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL31344401 | 0.64 | AKR1C3 (0.54) | TDP1AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL3346811 | 0.64 | CPB2 (0.36) | LMNATDP1CPB1CPB2MAPT | |
| SCHEMBL9661337 | 0.63 | KMT2A (0.41) | LMNATDP1CYP1A2HTT | |
| SCHEMBL3385979 | 0.63 | POLB (0.51) | LMNAPTGS1CYP1A2HTTNPSR1 | |
| SCHEMBL33145 | 0.63 | ALDH1A1 (0.43) | LMNATDP1CYP1A2MAPTHTT | |
| Hydrochloric Acid SCHEMBL21632067 | 0.62 | POLB (0.50) | LMNAPTGS1CYP1A2HTTNPSR1 | |
| SCHEMBL9367576 | 0.62 | EDNRB (0.46) | — | |
| SCHEMBL8975795 | 0.60 | ADORA2A (0.35) | CYP1A2 | |
| SCHEMBL10921794 | 0.59 | GAA (0.55) | LMNACYP1A2MAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | LMNA 102/4885TDP1 4364/4885AKR1C3 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.